Filing Analysis
Regulation FD Disclosure
Filed Mar 30, 2026
LOW
Jasper Therapeutics reported its financial results for the fourth quarter and full fiscal year ended December 31, 2025, and provided a corporate update.
Key Facts
- The filing reports financial results for the fiscal year and quarter ended December 31, 2025.
- The report was filed on March 30, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- A press release containing the detailed financial data and corporate update was furnished as Exhibit 99.1.
- The report was signed by Chief Financial Officer Herb Cross.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.